Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles

Molecular Pharmaceutics

Volumn 11, Issue 5, 2014, Pages 1611-1620

  Cheow, Wean Sin ^a   Kiew, Tie Yi ^a   Yang, Yue ^a   Hadinoto, Kunn ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

bioavailability enhancement; drug complexation; nanomedicine; nanopharmaceuticals; poorly soluble drug

Indexed keywords

DEXTRAN SULFATE; HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE; NANOPARTICLE; POLYELECTROLYTE; ANTIFUNGAL AGENT; POLYMER;

ARTICLE; COMPLEX FORMATION; MOISTURE; NANOMEDICINE; PARTICLE SIZE; PH; PRECIPITATION; PRIORITY JOURNAL; PROTON TRANSPORT; THERMOGRAVIMETRY; THERMOSTABILITY; ZETA POTENTIAL; CHEMISTRY;

ANTIFUNGAL AGENTS; HYPROMELLOSE DERIVATIVES; ITRACONAZOLE; NANOMEDICINE; NANOPARTICLES; POLYMERS;

EID: 84899892061     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400788p     Document Type: Article

References (32)

1. Serajuddin, A. T. M. Salt formation to improve drug solubility Adv. Drug Delivery Rev. 2007, 59 (7) 603-616
2. Brough, C.; Williams, R. O. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery Int. J. Pharm. 2013, 453 (1) 157-166
3. Brouwers, J.; Brewster, M. E.; Augustijns, P. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J. Pharm. Sci. 2009, 98 (8) 2549-2572
4. Yang, W.; Johnston, K. P.; Williams Iii, R. O. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats Eur. J. Pharm. Biopharm. 2010, 75 (1) 33-41
5. Pu, X. H.; Sun, J.; Han, J. H.; Lian, H.; Zhang, P.; Yan, Z. T.; He, Z. G. Nanosuspensions of 10-hydroxycamptothecin that can maintain high and extended supersaturation to enhance oral absorption: preparation, characterization and in vitro/in vivo evaluation J. Nanopart. Res. 2013, 15 (11) 2043
6. Miller, M. A.; DiNunzio, J.; Matteucci, M. E.; Ludher, B. S.; Williams, R. O.; Johnston, K. P. Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability Drug Dev. Ind. Pharm. 2012, 38 (5) 557-570
7. Tam, J. M.; McConville, J. T.; Williams, R. O.; Johnston, K. P. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution J. Pharm. Sci. 2008, 97 (11) 4915-4933
8. Laitinen, R.; Lobmann, K.; Strachan, C. J.; Grohganz, H.; Rades, T. Emerging trends in the stabilization of amorphous drugs Int. J. Pharm. 2013, 453 (1) 65-79
9. Matteucci, M. E.; Brettmann, B. K.; Rogers, T. L.; Elder, E. J.; Williams, R. O.; Johnston, K. P. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media Mol. Pharmaceutics 2007, 4 (5) 782-793
10. Lindfors, L.; Skantze, P.; Skantze, U.; Rasmusson, M.; Zackrisson, A.; Olsson, U. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening Langmuir 2006, 22 (3) 906-910
11. Dhumal, R. S.; Biradar, S. V.; Yamamura, S.; Paradkar, A. R.; York, P. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability Eur. J. Pharm. Biopharm. 2008, 70 (1) 109-115
12. Chen, X. X.; Young, T. J.; Sarkari, M.; Williams, R. O.; Johnston, K. P. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution Int. J. Pharm. 2002, 242 (1-2) 3-14
13. Mou, D. S.; Chen, H. B.; Wan, J. L.; Xu, H. B.; Yang, X. L. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility Int. J. Pharm. 2011, 413 (1-2) 237-244
14. Alonzo, D.; Zhang, G.; Zhou, D.; Gao, Y.; Taylor, L. Understanding the behavior of amorphous pharmaceutical systems during dissolution Pharm. Res. 2010, 27 (4) 608-618
15. Newman, A.; Knipp, G.; Zografi, G. Assessing the performance of amorphous solid dispersions J. Pharm. Sci. 2012, 101 (4) 1355-1377
16. Wyttenbach, N.; Janas, C.; Siam, M.; Lauer, M. E.; Jacob, L.; Scheubel, E.; Page, S. Miniaturized screening of polymers for amorphous drug stabilization (SPADS): Rapid assessment of solid dispersion systems Eur. J. Pharm. Biopharm. 2013, 84 (3) 583-598
17. Rumondor, A. C. F.; Ivanisevic, I.; Bates, S.; Alonzo, D. E.; Taylor, L. S. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems Pharm. Res. 2009, 26 (11) 2523-2534
18. Matteucci, M.; Paguio, J.; Miller, M.; Williams Iii, R.; Johnston, K. Flocculated amorphous nanoparticles for highly supersaturated solutions Pharm. Res. 2008, 25 (11) 2477-2487
19. Sertsou, G.; Butler, J.; Hempenstall, J.; Rades, T. Solvent change co-precipitation with hydroxypropyl methylcellulose phthalate to improve dissolution characteristics of a poorly water-soluble drug J. Pharm. Pharmacol. 2002, 54 (8) 1041-1047
20. Cheow, W. S.; Hadinoto, K. Green amorphous nanoplex as a new supersaturating drug delivery system Langmuir 2012, 28 (15) 6265-6275
21. Cheow, W. S.; Hadinoto, K. Green preparation of antibiotic nanoparticle complex as potential anti-biofilm therapeutics via self-assembly amphiphile-polyelectrolyte complexation with dextran sulfate Colloids Surf., B 2012, 92, 55-63
22. Ando, H. Y.; Radebaugh, G. W. Property-Based Drug Design and Preformulation. In Remington: The Science and Practice of Pharmacy, 21 st ed.; Troy, D. B., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005.
23. Peeters, J.; Neeskens, P.; Tollenaere, J. P.; Van Remoortere, P.; Brewster, M. E. Characterization of the interaction of 2-hydroxypropyl-β- cyclodextrin with itraconazole at pH 2, 4, and 7 J. Pharm. Sci. 2002, 91 (6) 1414-1422
24. Jung, J.-Y.; Yoo, S. D.; Lee, S.-H.; Kim, K.-H.; Yoon, D.-S.; Lee, K.-H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique Int. J. Pharm. 1999, 187 (2) 209-218
25. Verreck, G.; Six, K.; Van den Mooter, G.; Baert, L.; Peeters, J.; Brewster, M. E. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion: part I Int. J. Pharm. 2003, 251 (1-2) 165-174
26. Inkmann, E.; Holzgrabe, U. 1H and 13C nuclear magnetic resonance studies of the sites of protonation in itraconazole and fluconazole J. Pharm. Biomed. Anal. 1999, 20 (1-2) 297-307
27. Liu, J.; Takisawa, N.; Shirahama, K.; Abe, H.; Sakamoto, K. Effect of polymer size on the polyeletrolyte-surfactant interaction J. Phys. Chem. B 1997, 101 (38) 7520-7523
28. Six, K.; Verreck, G.; Peeters, J.; Binnemans, K.; Berghmans, H.; Augustijns, P.; Kinget, R.; Van den Mooter, G. Investigation of thermal properties of glassy itraconazole: identification of a monotropic mesophase Thermochim. Acta 2001, 376 (2) 175-181
29. Greco, S.; Authelin, J. R.; Leveder, C.; Segalini, A. A practical method to predict physical stability of amorphous solid dispersions Pharm. Res. 2012, 29 (10) 2792-2805
30. Negroni, R.; Arechavala, A. I. Itraconazole: pharmacokinetics and indications Arch. Med. Res. 1993, 24, 4387-4393
31. Yang, Y.; Hadinoto, K. A highly sustainable and versatile granulation method of nanodrugs via their electrostatic adsorption onto chitosan microparticles as the granulation substrates Int. J. Pharm. 2013, 452 (1-2) 402-411
32. Abdelwahed, W.; Degobert, G.; Fessi, H. Freeze-drying of nanocapsules: Impact of annealing on the drying process Int. J. Pharm. 2006, 324 (1) 74-82